(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(amc 2024-05-08)
Expected move: +/- 10.46%
Live Chart Being Loaded With Signals
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs...
Stats | |
---|---|
Dagens volum | 355 378 |
Gjennomsnittsvolum | 322 580 |
Markedsverdi | 77.78M |
EPS | $0 ( 2024-05-01 ) |
Neste inntjeningsdato | ( $-0.440 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.680 |
ATR14 | $0.00800 (0.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Moore Stephen Michael | Sell | 4 523 | Common Stock |
2024-03-15 | Hall Christopher M | Buy | 400 000 | Stock Option (right to buy) |
2024-03-15 | Chen Richard | Buy | 175 000 | Stock Option (right to buy) |
2024-03-15 | Tachibana Aaron | Buy | 175 000 | Stock Option (right to buy) |
2024-03-15 | Moore Stephen Michael | Buy | 100 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-62.68 |
Last 98 transactions |
Buy: 3 908 824 | Sell: 9 742 341 |
Volum Korrelasjon
Personalis Inc Korrelasjon
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Personalis Inc Korrelasjon - Valuta/Råvare
Personalis Inc Økonomi
Annual | 2023 |
Omsetning: | $73.48M |
Bruttogevinst: | $18.21M (24.78 %) |
EPS: | $-2.25 |
FY | 2023 |
Omsetning: | $73.48M |
Bruttogevinst: | $18.21M (24.78 %) |
EPS: | $-2.25 |
FY | 2022 |
Omsetning: | $65.05M |
Bruttogevinst: | $13.35M (20.52 %) |
EPS: | $-2.48 |
FY | 2021 |
Omsetning: | $85.49M |
Bruttogevinst: | $31.66M (37.03 %) |
EPS: | $-1.490 |
Financial Reports:
No articles found.
Personalis Inc
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.